Inflammatorischer Tumor als Differenzialdiagnose bei Hyperinflammation

Der inflammatorische myofibroblastische Tumor ist eine intermediär maligne Neoplasie des Kindesalters. Betroffene fallen durch B-Symptomatik und laborchemische Hyperinflammation auf. Therapieziel ist die vollständige chirurgische Entfernung des Tumors, ggf. muss eine neoadjuvante/adjuvante Polychemotherapie durchgeführt werden. Die 3-Jahres-Überlebensrate liegt bei > 90 %. Eine interdisziplinäre Zusammenarbeit aus pädiatrischer Rheumatologie, Immunologie, Radiologie, Hämatoonkologie und Pathologie beschleunigt die Diagnosestellung und optimiert das Patientenmanagement.

Publication History

Article published online:
26 February 2025

• Literatur

• 1 Webb TR, Slavish J, George RE. et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009; 9: 331-356
• 2 Cook JR, Dehner LP, Collins MH. et al. Anaplastic Lymphoma Kinase (ALK) Expression in the Inflammatory Myofibroblastic Tumor: A Comparative Immunohistochemical Study. Am J Surg Pathol 2001; 25: 1364-1371
• 3 Coffin CM, Hornick JL, Fletcher CDM. Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases. Am J Surg Pathol 2007; 31: 509-520
• 4 Surabhi VR, Chua S, Patel RP. et al. Inflammatory Myofibroblastic Tumors: Current Update. Radiol Clin North Am 2016; 54: 553-563
• 5 Coffin CM, Watterson J, Priest JR. et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995; 19: 859-872
• 6 Siemion K, Reszec-Gielazyn J, Kisluk J. et al. What do we know about inflammatory myofibroblastic tumors? – A systematic review. Adv Med Sci 2022; 67: 129-138
• 7 Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol 2021; 28: 44-58
• 8 Saab ST, Hornick JL, Fletcher CD. et al. IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?. Mod Pathol Off J U S Can Acad Pathol Inc 2011; 24: 606-612
• 9 Zhu L, Li J, Liu C. et al. Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series. J Thorac Dis 2017; 9: 598-609
• 10 Schmalzing M, Sander O, Seidl M. et al. Castleman’s disease in the rheumatological practice. Z Rheumatol 2024;
• 11 Butrynski JE, D’Adamo DR, Hornick JL. et al. Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor. N Engl J Med 2010; 363: 1727-1733
• 12 Casanova M, Brennan B, Alaggio R. et al. Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 2020; 127: 123-129
• 13 Karnak I, Şenocak ME, Ciftci AO. et al. Inflammatory myofibroblastic tumor in children: Diagnosis and treatment. J Pediatr Surg 2001; 36: 908-912
• 14 Dalton BGA, Thomas PG, Sharp NE. et al. Inflammatory myofibroblastic tumors in children. J Pediatr Surg 2016; 51: 541-544